NCT06844513Not yet recruiting
Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
HUGO RAS Robotic Platform for Radical Prostatectomy and Partial Nephrectomy: Comparison with the Da Vinci Robotic Platform
Source: ClinicalTrials.gov · Last updated 25 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- First submitted
- 10 Jan 2025
- Start date
- 31 Mar 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Prostate cancer, Kidney cancer
- NCT number
- NCT06844513
What you commit to
- Study type: Interventional
- Planned participants: 800
- From 31 Mar 2025 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Expression of a preference for radical treatment other than surgery (e.g., external radiotherapy).
Other illness
- Patients with Prostate Cancer (Group A)
- Metastatic prostate cancer (M1).
- Other conditions deemed by healthcare professionals to contraindicate inclusion in the study.
- Patients with Kidney Cancer (Group B)
- Metastatic kidney cancer (M1).
- Other conditions deemed by healthcare professionals to contraindicate inclusion in the study.
Other
- Indication for radical nephrectomy.
Who the study is looking for
- Patients with Prostate Cancer (Group A)
- Age ≥ 18 years.
- Life expectancy greater than 10 years.
- Diagnosis of prostate cancer following prostate needle biopsy.
- Clinical stage cT1-T3b, N0-1 disease.
- Positive anesthetic fitness assessment for robot-assisted radical prostatectomy.
- Provision of informed consent for the study.
- Patients with Kidney Cancer (Group B)
- Age ≥ 18 years.
- Radiological diagnosis of organ-confined kidney cancer at clinical stage T1a or T1b.
- Underwent CT and/or MRI of the abdomen with contrast medium.
- Positive anesthetic fitness assessment for robot-assisted partial nephrectomy.
- Provision of informed consent for the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.